Literature DB >> 21109768

Do mTOR inhibitors still have a future in ADPKD?

Norberto Perico, Giuseppe Remuzzi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21109768     DOI： 10.1038/nrneph.2010.153

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  9 in total

Review 1.  Autosomal dominant polycystic kidney disease.

Authors:  Vicente E Torres; Peter C Harris; Yves Pirson
Journal:  Lancet       Date:  2007-04-14       Impact factor: 79.321

2.  The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease.

Authors:  Jonathan M Shillingford; Noel S Murcia; Claire H Larson; Seng Hui Low; Ryan Hedgepeth; Nicole Brown; Chris A Flask; Andrew C Novick; David A Goldfarb; Albrecht Kramer-Zucker; Gerd Walz; Klaus B Piontek; Gregory G Germino; Thomas Weimbs
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-27       Impact factor: 11.205

3.  Sirolimus and kidney growth in autosomal dominant polycystic kidney disease.

Authors:  Andreas L Serra; Diane Poster; Andreas D Kistler; Fabienne Krauer; Shagun Raina; James Young; Katharina M Rentsch; Katharina S Spanaus; Oliver Senn; Paulus Kristanto; Hans Scheffel; Dominik Weishaupt; Rudolf P Wüthrich
Journal:  N Engl J Med       Date:  2010-06-26       Impact factor: 91.245

4.  Everolimus in patients with autosomal dominant polycystic kidney disease.

Authors:  Gerd Walz; Klemens Budde; Marwan Mannaa; Jens Nürnberger; Christoph Wanner; Claudia Sommerer; Ulrich Kunzendorf; Bernhard Banas; Walter H Hörl; Nicholas Obermüller; Wolfgang Arns; Hermann Pavenstädt; Jens Gaedeke; Martin Büchert; Christoph May; Harald Gschaidmeier; Stefan Kramer; Kai-Uwe Eckardt
Journal:  N Engl J Med       Date:  2010-06-26       Impact factor: 91.245

Review 5.  Mechanisms of progression in autosomal dominant polycystic kidney disease.

Authors:  J J Grantham
Journal:  Kidney Int Suppl       Date:  1997-12       Impact factor: 10.545

6.  Sirolimus therapy to halt the progression of ADPKD.

Authors:  Norberto Perico; Luca Antiga; Anna Caroli; Piero Ruggenenti; Giorgio Fasolini; Mariateresa Cafaro; Patrizia Ondei; Nadia Rubis; Olimpia Diadei; Giulia Gherardi; Silvia Prandini; Andrea Panozo; Rodolfo Flores Bravo; Sergio Carminati; Felipe Rodriguez De Leon; Flavio Gaspari; Monica Cortinovis; Nicola Motterlini; Bogdan Ene-Iordache; Andrea Remuzzi; Giuseppe Remuzzi
Journal:  J Am Soc Nephrol       Date:  2010-05-13       Impact factor: 10.121

7.  Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease.

Authors:  Ming Wu; Patricia R Wahl; Michel Le Hir; Ying Wackerle-Men; Rudolf P Wuthrich; Andreas L Serra
Journal:  Kidney Blood Press Res       Date:  2007-06-27       Impact factor: 2.687

8.  Sirolimus reduces polycystic liver volume in ADPKD patients.

Authors:  Qi Qian; Hui Du; Bernard F King; Sumedha Kumar; Patrick G Dean; Fernando G Cosio; Vicente E Torres
Journal:  J Am Soc Nephrol       Date:  2008-01-16       Impact factor: 10.121

9.  Computed tomography evaluation of autosomal dominant polycystic kidney disease progression: a progress report.

Authors:  Luca Antiga; Marina Piccinelli; Giorgio Fasolini; Bogdan Ene-Iordache; Patrizia Ondei; Simona Bruno; Giuseppe Remuzzi; Andrea Remuzzi
Journal:  Clin J Am Soc Nephrol       Date:  2006-06-14       Impact factor: 8.237
  9 in total
  10 in total

Review 1.  Ion channels in renal disease.

Authors:  Ivana Y Kuo; Barbara E Ehrlich
Journal:  Chem Rev       Date:  2012-07-18       Impact factor: 60.622

Review 2.  Cilium, centrosome and cell cycle regulation in polycystic kidney disease.

Authors:  Kyung Lee; Lorenzo Battini; G Luca Gusella
Journal:  Biochim Biophys Acta       Date:  2011-03-02

3.  Polycystin-1 but not polycystin-2 deficiency causes upregulation of the mTOR pathway and can be synergistically targeted with rapamycin and metformin.

Authors:  Djalila Mekahli; Jean-Paul Decuypere; Eva Sammels; Kirsten Welkenhuyzen; Joost Schoeber; Marie-Pierre Audrezet; Anniek Corvelyn; Georges Dechênes; Albert C M Ong; Martijn J Wilmer; Lambertus van den Heuvel; Geert Bultynck; Jan B Parys; Ludwig Missiaen; Elena Levtchenko; Humbert De Smedt
Journal:  Pflugers Arch       Date:  2013-11-06       Impact factor: 3.657

4.  Folate-conjugated rapamycin slows progression of polycystic kidney disease.

Authors:  Jonathan M Shillingford; Christopher P Leamon; Iontcho R Vlahov; Thomas Weimbs
Journal:  J Am Soc Nephrol       Date:  2012-08-02       Impact factor: 10.121

5.  Measuring and estimating GFR and treatment effect in ADPKD patients: results and implications of a longitudinal cohort study.

Authors:  Piero Ruggenenti; Flavio Gaspari; Antonio Cannata; Fabiola Carrara; Claudia Cella; Silvia Ferrari; Nadia Stucchi; Silvia Prandini; Bogdan Ene-Iordache; Olimpia Diadei; Norberto Perico; Patrizia Ondei; Antonio Pisani; Erasmo Buongiorno; Piergiorgio Messa; Mauro Dugo; Giuseppe Remuzzi
Journal:  PLoS One       Date:  2012-02-28       Impact factor: 3.240

Review 6.  Mammalian target of rapamycin inhibition in polycystic kidney disease: From bench to bedside.

Authors:  Hyun-Jung Kim; Charles L Edelstein
Journal:  Kidney Res Clin Pract       Date:  2012-08-10

Review 7.  Pathways, perspectives and pursuits in polycystic kidney disease.

Authors:  L V K S Bhaskar; Ramprasad Elumalai; Soundararajan Periasamy
Journal:  J Nephropharmacol       Date:  2015-12-13

Review 8.  mTOR Inhibition: From Aging to Autism and Beyond.

Authors:  Matt Kaeberlein
Journal:  Scientifica (Cairo)       Date:  2013-11-26

9.  Extracellular vesicles and exosomes generated from cystic renal epithelial cells promote cyst growth in autosomal dominant polycystic kidney disease.

Authors:  Hao Ding; Linda Xiaoyan Li; Peter C Harris; Junwei Yang; Xiaogang Li
Journal:  Nat Commun       Date:  2021-07-27       Impact factor: 14.919

Review 10.  Recent Discoveries in Epigenetic Modifications of Polycystic Kidney Disease.

Authors:  Sarah A Bowden; Euan J Rodger; Aniruddha Chatterjee; Michael R Eccles; Cherie Stayner
Journal:  Int J Mol Sci       Date:  2021-12-11       Impact factor: 5.923
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.